We highlight the hypophosphatasia (HPP) community and share insights into the daily challenges of this rare metabolic condition. Listening to and learning from this patient community supports progress in HPP care. #WorldHPPDay #Hypophosphatasia #RareDisease

#ESMO25 highlighted why we do what we do — driving innovation, impact and hope for patients. Thank you to the global oncology community for advancing progress and pushing boundaries.

On #GlobalPNHAwarenessDay, we’re joining the #RareDisease community around the world to bring attention to paroxysmal nocturnal hemoglobinuria (#PNH). By deepening awareness and understanding of this rare disease, we’re committed to improving outcomes for those living with PNH.

We’re proud to announce a historic agreement with @POTUS to lower the cost of prescription medicines for American patients while preserving the America’s cutting-edge biopharmaceutical innovation. Learn more: https://t.co/qe6cV9GxA7 #AZN #News

#News Today we announced we will invest US$4.5 billion in a new manufacturing facility in Virginia— which includes a proposed $500m increase to enhance manufacturing capabilities to bring a broader range of medicines, including cancer, to patients in the US and worldwide. #AZN

We’re pushing the boundaries of science to redefine outcomes, reduce economic burden and prioritize prevention in respiratory and other immune-mediated diseases. Our goal is that every patient gets the care they need and deserve. Read more: https://t.co/xe8ywdn2wV

On #aHUSDay, we recognise those living with atypical haemolytic uraemic syndrome. We are inspired by the strength and resilience of the #aHUS community and remain dedicated to improving care for those affected by this severe and devastating disease. #aHUS24Sept

Meet the 2025 #YoungHealthProgramme changemakers! From Impact Fellows to Scholars, these young leaders are advancing health equity around the world. Partnering with @OneYoungWorld & @AFSyouthassembly to support the next generation.

#News for #Investors and #Media📈 Our H1 results are now available and show strong momentum, with Total Revenue up 11% and remarkable pipeline delivery. https://t.co/wKOjuPRQD3 #AZN #FinancialResults

#News for #investors and #media We’re investing $50 billion in medicines manufacturing and R&D in the US by 2030, including the largest single manufacturing investment we’ve ever made—a new state-of-the-art drug substance manufacturing centre in Virginia. #AZN

Explore our Sustainability Impact Publication which highlights how we're taking action on climate and nature, health equity and health systems resilience. Through collaboration, we can build a healthier future for people, society & planet: https://t.co/RcO1AordVS

#News for #Investors and #Media📈 We continued our strong growth momentum into 2025 with Total Revenue increasing by 10%, driven by double-digit growth across Oncology/ Haematology and BioPharmaceuticals. #AZN #FinancialResults

🌍 Calling all youth leaders in global health equity! Join our Young Health Programme Impact Fellowship for a fully funded @OneYoungWorld scholarship, financial grant, and development opportunities. Apply now: https://t.co/4fGu1ACk7g #OYW25 #YoungHealthProgramme

Are you a young leader advocating for greater health equity? Now’s the time to apply to the Young Health Programme Impact Fellowship in partnership with @OneYoungWorld: https://t.co/IzM843w6wX #YoungHealthProgramme #OYW25

@FutureBiogas We celebrated this milestone with Dr Miatta Fahnbulleh (@Miatsf), MP, Minister for Energy Consumers, where we discussed the critical role of projects like this in progressing a cleaner, more sustainable energy network for the UK. Learn more: 👉

@FutureBiogas This clean heat solution cuts CO2 emissions and drives sustainable farming practices. It’s all part of our commitment to sustainability and a healthier future.

This week we hit a major milestone in our Ambition Zero Carbon journey! We partnered with @FutureBiogas to launch the UK’s first unsubsidised biomethane plant. We're proud to be the first UK pharma company using biomethane at scale to power medicine discovery and production.

2024 was another year of double-digit growth with continued scientific progress across all Therapy Areas. Our total annual dividend increased by 7% to $3.10 per share and will further increase in 2025. Watch CEO Pascal Soriot share our Full Year and Q4 2024 results. #AZN

We’re setting new standards in sustainable science, becoming the first organisation to achieve the new @My_Green_Lab 2.0 Certification. We have over 78 lab spaces certified and 65 achieved the highest certification level – Green. #WhatScienceCanDo #GreenLabs #RacetoZero

From lab to patient, we’re focused on sustainable science and leveraging digital advances such as electronic product information (ePI), unlocking benefits for people, society and the planet. Learn more: https://t.co/kodwXZaA2W